Back to Newsroom

Cempra, Inc., Provides Update on Clinical Development of Solithromycin and Taksta(TM)

CHAPEL HILL, N.C., Dec. 16, 2013 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), today provided an update on the clinical development of solithromycin and Taksta(TM). Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will host a conference call and webcast at 4:30 p.m. EST, today, to discuss the current status of the company’s clinical programs.